Editor's key points † Dexmedetomidine has been used to prolong the duration of local anaesthetics (LAs). † In this meta-analysis, nine randomized controlled trials on perineural dexmedetomidine in neuraxial and peripheral nerve blocks were selected. † Dexmedetomidine prolonged block duration. † More studies are required to establish the safety of using dexmedetomidine as a perineural adjunct to LAs.
sensory and motor block onset time 27 or no effect on sensory and motor block duration 24 with the use of perineural dexmedetomidine. The primary objective of this quantitative review is to determine whether the administration of perineural dexmedetomidine as an LA adjuvant for neuraxial and peripheral nerve blocks can prolong the duration of analgesia compared with LA alone.
Methods
The PRISMA 28 recommendations were followed in the preparation of this manuscript.
Eligibility criteria
We sought to identify all randomized controlled trials (RCTs) that examined the effects of adding perineural dexmedetomidine to LA (dexmedetomidine group) compared with LA alone (control group) on neuraxial or peripheral nerve block characteristics, postoperative analgesia, and dexmedetomidine-related side-effects in surgical patients undergoing regional anaesthesia. Blocks performed for either anaesthesia or postoperative analgesia were included. RCTs were excluded if dexmedetomidine was used as a stand-alone perineural agent without LA, 29 or administered via a nonperineural route, 23 24 30 -38 if continuous nerve blocks were performed, 39 40 and if blocks were performed in paediatric patients where block characteristics could not be assessed. 41 -44 Only trials that explicitly mentioned obtaining approval from the local ethics committee or institutional review board were considered. The use of dexmedetomidine as part of i.v. regional anaesthesia (Bier block) was not considered for the purposes of this review.
Literature search
We retrieved RCTs from the US National Library of Medicine database, MEDLINE; the Excerpta Medica database, Embase; Cochrane Database of Systematic Reviews; and Cochrane Central Register of Controlled Trials databases (January 1985 -August 2012). The search terms dexmedetomidine and medetomidine were used in combination with the search terms perineural, adjuvant, adjunct, and admixture. Searches were combined using the Boolean operator AND with medical subject headings analgesia/pain relief/pain control/pain prevention/and pain management and the medical subject headings regional anaesthesia/nerve block/ block/neuraxial block/central block/peripheral block. The search was limited to trials published in the English language. We also reviewed the reference lists of selected trials for additional RCTs. Trials that are unpublished or in progress were not included.
Data collection and presentation
The two authors (F.W.A. and R.B.) independently evaluated the methodological quality of the included trials using the Jadad score; 45 and a final score was designated by consensus for each RCT. We selected sensory block duration as the primary endpoint, while motor block duration, sensory and motor block onset time, analgesic consumption, time to first analgesic request, pain scores, 46 and dexmedetomidinerelated adverse effects (hypotension, bradycardia, respiratory depression, and postoperative sedation) 47 48 were defined as secondary endpoints. The authors each used a standardized data sheet to extract and record trial results, which were compared and any differences were resolved by reexamination of the source trials.
Meta-analysis
Data entry was performed by one author (F.W.A.) and rechecked by another (R.B.). Meta-analytic techniques (Revman 5.1, Cochrane Library, Oxford, UK) were used to pool data whenever possible. Data from trials with more than two intervention groups receiving different doses of dexmedetomidine via the same route were combined into a single group as recommended by the Cochrane Handbook. 49 Dichotomous and continuous outcomes were analysed using random-effects modelling. The odds ratio (OR) and 95% confidence intervals (CIs) are reported for dichotomous outcomes, while the standardized mean difference and 95% CI are reported for continuous outcomes. Differences were considered statistically significant when the 95% CI did not include 1 for OR and 0 for the standardized mean difference. Heterogeneity of the pooled results was assessed using the I 2 statistic.
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Results
We retrieved 37 articles, of which nine met our inclusion criteria. 25 -27 51 -56 Tables 1 and 2 All nine trials reviewed herein used a long-acting LA, namely ropivacaine, 53 bupivacaine, 26 27 51 52 54 56 and levobupivacaine (Table 1) . 25 55 We did not identify any RCTs that investigated the use of peripheral dexmedetomidine for truncal or lower extremity blocks, or neuraxial dexmedetomidine in epidural or caudal blocks. Two trials included two dexmedetomidine groups 51 52 ('low dose' and 'high dose').
Sensory block duration
Data regarding sensory block duration were available from all trials reviewed and are presented in Figure 2 . Intrathecal administration of dexmedetomidine as part of spinal anaesthesia prolonged the mean sensory block duration by 150 min (95% CI: 95.94, 204.75, P,0.00001), which is a relative increase of 72% compared with LAs alone. The heterogeneity among the pooled studies in this subgroup was significant (I 2 ¼0.95; P,0.00001).
The data signal that peripheral dexmedetomidine used in a BP block at the axillary, 25 (Table 3) . Administering perineural dexmedetomidine as part of a BP block resulted in a prolongation of motor block duration by 268 min (95% CI: 15.47, 520.06, P¼0.04) or 87%, and an increase in time to first analgesic request by 345 min (95% CI: 102.68, 587.23, P¼0.005) or 70% compared with LAs alone. The sensory and motor block onset times were similar between the dexmedetomidine and control groups (Table 3) .
Dexmedetomidine-related adverse effects
Because of the diversity in the definitions of dexmedetomidine-related adverse effects in the reviewed trials, the results of these outcomes are reported as 'standardized units'. The incidence of hypotension was similar between the dexmedetomidine and the control groups (Table 3 ). The incidence of bradycardia was higher in patients who received dexmedetomidine as part of a BP block (7% vs 0%, P¼0.03), but there was no difference with intrathecal administration. The observed bradycardia was transient, successfully reversed by i.v. atropine administration, and did not recur later during the postoperative period.
Respiratory depression was explicitly assessed in four trials. 25 27 52 55 None of the patients in these trials experienced respiratory depression. The incidence of postoperative sedation was evaluated in four trials 26 51 -53 that examined the intrathecal administration of dexmedetomidine; a six-point measurement scale was used in two of the trials 51 52 and a four-point scale was used in the other two trials. 26 53 The heterogeneity of scales used and the inconsistency in reporting rates of occurrence precluded any quantitative analyses. Qualitatively, one trial 52 reported higher sedation levels in a group of patients receiving high-dose intrathecal dexmedetomidine (15 mg) without specifying the actual rate of occurrence, while Perineural dexmedetomidine the patients who received intrathecal dexmedetomidine as an adjunct to spinal anaesthesia and those who did not. We could not quantitatively analyse our remaining secondary endpoints (pain scores, analgesic consumption) due to inconsistent reporting and heterogeneous assessment protocols within and between the source trials. Qualitatively, these results favour the dexmedetomidine group and are presented in Table 4 .
Discussion
Our review of the literature suggests that the use of dexmedetomidine as a perineural adjuvant can prolong the durations of both sensory and motor block produced by long-acting LAs in spinal blocks. For BP blocks, perineural dexmedetomidine can prolong the duration of motor block; however, the trend towards prolonged sensory block did not reach statistical significance. Dexmedetomidine also hastens the onset of sensory block in spinal anaesthesia and prolongs the time to first analgesic request in the setting of both spinal anaesthesia and BP block. The advantages of dexmedetomidine may be offset by an increased likelihood of transient, reversible bradycardia, and the prolongation of motor block when it is undesirable.
In the context of perineural adjuvants, the efficacy of dexmedetomidine appears to be comparable with buprenorphine 16 duration of shorter acting 62 -64 but not long-acting 65 66 LAs, this review demonstrated that dexmedetomidine clearly prolonged the block duration of long-acting LAs. Also, while clonidine produces preferential extension of sensory block, 67 our review suggests that dexmedetomidine prolongs both sensory and motor block, a difference that may be disadvantageous by delaying rehabilitation and/or discharge, or worse, precipitating falls. The results of our review are subject to several limitations. The trials included herein were small and characterized by high levels of heterogeneity, factors that limit the clinical combinability of the source trials, and the generalizability of our results. Similarly, the present safety data, however limited, may not apply to other block types as local neurotoxicity and systemic uptake are both influenced by site-specific perfusion levels. 15 The generalizability of this review is further limited by publication bias as all source studies originated from Middle Eastern countries, which may or may not reflect less stringent Institutional Review Board and/or editorial board policies. 68 The lack of United States (US) Food 27 55 and onsets of sensory 25 27 and motor 25 27 block may have contributed to the statistically significant heterogeneity of the pooled results. Despite the variability in dexmedetomidine doses used, it is nonetheless noteworthy that significantly prolonged durations of sensory and motor blocks and also time to first analgesic request were achieved even with the lowest doses of dexmedetomidine, namely, 3 mg for intrathecal and 30 mg of peripheral administration.
While we could not demonstrate any association between perineural dexmedetomidine and the frequency of hypotension or respiratory depression, the trials examined herein were not specifically designed to assess safety. While dexmedetomidine may appear safe in the short term, 83 84 systematic preclinical and subsequent human neurotoxicity data, including the investigation of potential delayed adverse neurological effects and effects related to prolonged perineural exposure, are lacking. 85 Indeed, relevant neurotoxicity data seem contradictory; while a number of reports suggest that dexmedetomidine is protective against hypoxic-ischaemic neuronal injury in rat and human neonatal asphyxia models, 86 -92 dexmedetomidine has also been shown to cause moderate to severe demyelination in white matter when doses as high as 6.1 mg kg 21 were administered via an epidural route in rabbits. 93 While the doses used in the trials reviewed herein did not exceed 0.2 mg kg 21 for intrathecal and 1 mg kg 21 for peripheral administration, the hazards of drawing conclusions of safety based on isolated small animal data are self-evident. 15 Finally, none of the reviewed trials justified the safety and compatibility of their dexmedetomidine -LA mixture for peripheral and neuraxial use. In summary, dexmedetomidine is a potential LA adjuvant that can exhibit a facilitatory effect when administered intrathecally as part of spinal anaesthesia or peripherally as part of a BP block. However, there are presently insufficient safety data to support the use of perineural dexmedetomidine in the clinical setting.
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